Doseology names interim CEO, settles $13,548 debt in shares
What's the deal? Doseology SciencesDealroom has a profile for this one. Try Dealroom → (CSE: MOOD) named Kareem Baalbaki interim chief executive officer, interim chief financial officer, and director on September 30, 2026, as former CEO Chris Jackson and former CFO Chris Cherry resigned. The Kelowna-based company also added Jeremy Wright as a director.
The moves came alongside a completed shares-for-debt settlement. DoseologyDealroom has a profile for this one. Try Dealroom →, which makes oral pouch and functional stimulant consumer products, issued 75,268 common shares at $0.18 each to clear $13,548.39 in accrued consulting fees.
Who's Baalbaki? An operations and supply chain executive with more than a decade scaling high-growth companies. As chief supply chain officer at Revive SuperfoodsDealroom has a profile for this one. Try Dealroom →, he helped grow annual revenues from about $10 million to $150 million.
The board addition: Wright, a CPA, joins while serving as CFO of Avant Brands. He was founding CFO of GTEC HoldingsDealroom has a profile for this one. Try Dealroom →, helping raise over $45 million before its TSX uplisting, and later CFO of Alpha Cognition, where he assisted in raising more than $20 million. He is a former senior manager at DeloitteDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The settlement shares carry resale restrictions under Canadian securities laws. The immediate share-price impact was not disclosed.
The signal: The leadership overhaul and small debt clean-up point to a company tightening operations and finances. Investors will watch whether the new team can stabilise the business and advance its oral pouch initiatives.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
